By Bhanvi Satija LONDON, Jan 22 (Reuters) - Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are ...

Dow Jones Top Company Headlines at 7 AM ET: Moderna, Merck Report Positive Results From Cancer-Vaccine Study | GSK ... Moderna and Merck's cancer vaccine reduced the risk of relapse or death for ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna has filed approval applications for a seasonal flu vaccine it expects to become a critical source of future revenue growth. The company on Monday said it submitted clearance requests with ...

Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable therapies. The heavily back-loaded deal will see Moderna hand over just $3 ...

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions. Moderna Inc. shares fell sharply on ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's chief technical ...